|
As a pharmaceutical/healthcare professional, you know how valuable KOLs are to your organisation and how they contribute to the success of your clinical research. In today's competitive and challenging market, it is vital that relationship between the pharmaceutical/healthcare industry and KOLs are not only built but nurtured and maintained.
Identifying and engaging KOLs for your organisation is crucial to the success of your product. Entering European markets is a challenge faced by the pharmaceutical industry with ever-changing pricing structures and regulations. Working closely and adopting a culture of transparent collaboration and engagement with KOLs helps overcome some of these challenges.
SMi is proud to present KOL Knowledge Leaders focussed to keepour audience up-to-date with developments in the ever-changing KOL sphere.
|
 |
Why should you attend this event?
Hear about all the latest regulatory guidance in the European markets
Identify and engage with KOL through effective social media and traditional channels
Gain an insight into current transparent and flexible relationships
Improve your relationship with key leaders
Overcoming cultural barriers and dealing with change management
Establishing the return on investment for your KOL and MSL management
Develop a successful KOL management program
Hear keynote addresses from:
Confirmed chairs:
• Simon Twigden, Team Leader, Special Projects, Bayer
• David Gillen, Medical Director, Celgene
Confirmed KOLs:
• Audrey Craven, President, European Federation of Neurological Associations (EFNA)
• Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
• Mario Ottiglio, Associate Director, Public Affairs & Global Health Policy, IFPMA
• Charles Alessi, Chairman, National Association of Primary Care (NAPC)
• Susanna Palkonen, Executive Officer, European Federation of Allergy and Airways Diseases Patients Associations
• Prof Wisia Wedzicha, Professor Respiratory Medicine, University College London
Confirmed speakers:
• Michal Konstacky, Medical Affairs Director, Takeda
• Ales Kminek, Medical Marketing Director, AstraZeneca
• Christian Felter, Senior Director, Medical Affairs, Astellas Pharma
• Sanjita Panchal, Medical Scientific Liaison, Merck
• Shaul Brazil, Barrister, BCL Burton Copeland
• Keith Allan, Head of Global Advocacy, Novartis
• Lurdes Reis, Marketing Manager, Bayer
• David Gillen, Medical Director, Celgene
• Philippe Fonjallaz, Medical Affairs, Merck Serono
• Neil Ranasinghe, Medical Sciences Manager, Oncology, Immunology & Neuroscience, Bristol-Myers Squibb
Confirmed joint presentation with KOL:
• Johanna Jarvis, Managing Director, Jarvis Consulting & Tim Curry, Assistant Head of Nursing, Royal College of Nursing
• Miriam George, CEO, PDC Healthcare & Raman Aulakh, Director, The Ashcroft Clinic - Private Hospital Facility
